SCHEMBL7649299

SCHEMBL7649299

C[C](Cc1ccccc1)NC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
L3MBTL1 Q9Y468 2/20 0.56
MAPK1 P28482 1/20 0.56
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
MGLL Q99685 1/20 0.50
ENPP2 Q13822 2/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308290 0.84 ALDH1A1 (0.63) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL7355501 0.84 ALDH1A1 (0.63) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL27425940 0.84 ALDH1A1 (0.63) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL234454 0.84 LMNA (0.62) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL10980848 0.83 ALDH1A1 (0.59) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL16945695 0.81 ALDH1A1 (0.59) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL8891764 0.81 ALDH1A1 (0.59) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL11388818 0.81 ALDH1A1 (0.58) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL10508938 0.81 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1NPC1RAB9A
SCHEMBL550351 0.80 NPC1 (0.60) ALDH1A1L3MBTL1MAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6479265-B1 Catalytic antibodies which hydrolyze primary amides and methods for eliciting and use of such antibodies IGEN INTERNATIONAL, INC. 2002-11-12 US disclosed
US-5900237-A GENETIC ENGINEERING IGEN INTERNATIONAL, INC. (US) 1999-05-04 US disclosed
EP-0696318-A4 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN INC (US) 1998-04-15 EP disclosed
EP-0696318-A1 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN, INC. (a California corporation) (US) 1996-02-14 EP disclosed
WO-1994025573-A1 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES IGEN, INC. (US) 1994-11-10 WO disclosed
EP-0538374-A4 ASPARTIC PROTEASE INHIBITORS 1993-05-19 EP disclosed
EP-0538374-A1 ASPARTIC PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-04-28 EP disclosed
WO-1992000954-A1 ASPARTIC PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1992-01-23 WO disclosed